In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 1 ( 2022-1-21), p. e0262903-
Abstract:
Africa denotes unique facies for hepatocellular carcinoma (HCC) characterized by a conjunction of low sensitization, restricted access to diagnosis and treatment and associated with the highest incidence and mortality in the world. We investigated whether hepatitis B (HBV), C (HCV) and D (VHD) viruses were etiological agents of HCC in Africa. Methods Relevant articles were searched in PubMed, Web of Science, African Index Medicus, and African Journal Online databases, as well as manual searches in relevant reviews and included articles. Analytical studies from Africa evaluating the association between HCC development and HBV, HCV, and HDV were included. Relevant studies were selected, data extracted, and the risk of bias assessed independently by at least 2 investigators. The association was estimated using odds ratios (OR) and their 95% confidence interval (95% CI) determined by a random-effects model. Sources of heterogeneity were determined by subgroup analyses. Results A total of 36 case-control studies were included. With controls having non-hepatic disease, the overall results suggested a significantly increased risk of HCC in patients with HBV (HBeAg (OR = 19.9; 95% CI = [3.7–105.2]), HBsAg (OR = 9.9; 95%) CI = [6.2–15.6] ) and DNA (OR = 8.9; 95% CI = [5.9–13.4]); HCV (Anti-HCV (OR = 9.4; 95% CI = [6.3–14.0] ) and RNA (OR = 16.5; 95% CI = [7.8–34.6]); HDV (Anti-VHD, (OR = 25.8; 95% CI = [5.9–112.2] ); and HBV/HCV coinfections (HBV DNA/HCV RNA (OR = 22.5; 95% CI = [1.3–387.8]). With apparently healthy controls, the overall results suggested a significantly increased risk of HCC in patients with HBV (HBsAg, (OR = 8.9; 95% CI = [6.0–13.0] ); HCV (Anti-HCV, (OR = 7.7; 95% CI = [5.6–10.6]); and HBV/HCV coinfections (HBsAg/Anti-HCV (OR = 7.8; 95% CI = [4.4–13.6] ) Substantial heterogeneity and the absence of publication bias were recorded for these results. Conclusions In Africa, HBV/HCV coinfections and HBV, HCV, and HDV infections are associated with an increased risk of developing HCC. The implementation of large-scale longitudinal and prospective studies including healthy participants to search for early biomarkers of the risk of progression to HCC is urgently needed.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0262903
DOI:
10.1371/journal.pone.0262903.g001
DOI:
10.1371/journal.pone.0262903.g002
DOI:
10.1371/journal.pone.0262903.g003
DOI:
10.1371/journal.pone.0262903.g004
DOI:
10.1371/journal.pone.0262903.g005
DOI:
10.1371/journal.pone.0262903.t001
DOI:
10.1371/journal.pone.0262903.s001
DOI:
10.1371/journal.pone.0262903.s002
DOI:
10.1371/journal.pone.0262903.s003
DOI:
10.1371/journal.pone.0262903.s004
DOI:
10.1371/journal.pone.0262903.s005
DOI:
10.1371/journal.pone.0262903.s006
DOI:
10.1371/journal.pone.0262903.s007
DOI:
10.1371/journal.pone.0262903.s008
DOI:
10.1371/journal.pone.0262903.s009
DOI:
10.1371/journal.pone.0262903.s010
DOI:
10.1371/journal.pone.0262903.s011
DOI:
10.1371/journal.pone.0262903.s012
DOI:
10.1371/journal.pone.0262903.s013
DOI:
10.1371/journal.pone.0262903.s014
DOI:
10.1371/journal.pone.0262903.s015
DOI:
10.1371/journal.pone.0262903.s016
DOI:
10.1371/journal.pone.0262903.s017
DOI:
10.1371/journal.pone.0262903.s018
DOI:
10.1371/journal.pone.0262903.s019
DOI:
10.1371/journal.pone.0262903.s020
DOI:
10.1371/journal.pone.0262903.s021
DOI:
10.1371/journal.pone.0262903.s022
DOI:
10.1371/journal.pone.0262903.s023
DOI:
10.1371/journal.pone.0262903.r001
DOI:
10.1371/journal.pone.0262903.r002
DOI:
10.1371/journal.pone.0262903.r003
DOI:
10.1371/journal.pone.0262903.r004
DOI:
10.1371/journal.pone.0262903.r005
DOI:
10.1371/journal.pone.0262903.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Bookmarklink